News coverage about Acasti Pharma (NASDAQ:ACST) has trended somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acasti Pharma earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.7822671489491 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Acasti Pharma (ACST) traded down 2.0581% during mid-day trading on Tuesday, reaching $1.3515. The company’s stock had a trading volume of 6,517 shares. The company has a 50-day moving average price of $1.32 and a 200-day moving average price of $1.31. Acasti Pharma has a 12-month low of $1.11 and a 12-month high of $2.46. The firm’s market cap is $19.88 million.
ILLEGAL ACTIVITY WARNING: “Acasti Pharma (NASDAQ:ACST) Receives Media Sentiment Score of 0.21” was posted by BBNS and is the sole property of of BBNS. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://baseballnewssource.com/markets/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-acasti-pharma-acst-stock-price/1699204.html.
About Acasti Pharma
Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).
Receive News & Ratings for Acasti Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma Inc. and related companies with our FREE daily email newsletter.